Bhaskar Anand Reata Pharmaceuticals Inc (RETA) insider trading activity

Bhaskar Anand is SVP, Chief Accounting Officer of REATA PHARMACEUTICALS INC. Currently has a direct ownership of 0 shares of RETA, which is worth approximately $0. The most recent transaction as insider was on Sep 26, 2023, when has been sold 24,089 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Bhaskar Anand Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 26 2023	SELL Sale (or disposition) back to the issuer	-	24,089 Reduced 100.0%	0 Class A Common Stock
Sep 05 2023	SELL Open market or private sale	$68,695 $169.2 p/Share	406 Reduced 1.66%	24,089 Class A Common Stock
Aug 16 2023	SELL Open market or private sale	$35,368 $168.42 p/Share	210 Reduced 0.85%	24,495 Class A Common Stock
Aug 15 2023	SELL Open market or private sale	$32,628 $169.06 p/Share	193 Reduced 0.78%	24,705 Class A Common Stock
Jun 14 2023	SELL Open market or private sale	$239,243 $102.11 p/Share	2,343 Reduced 8.6%	24,898 Class A Common Stock
Jun 14 2023	BUY Exercise of conversion of derivative security	$42,673 $27.32 p/Share	1,562 Added 5.42%	27,241 Class A Common Stock
May 16 2023	SELL Open market or private sale	$11,029 $81.1 p/Share	136 Reduced 0.53%	25,679 Class A Common Stock
May 15 2023	SELL Open market or private sale	$81,681 $85.98 p/Share	950 Reduced 3.55%	25,815 Class A Common Stock
Mar 07 2023	SELL Open market or private sale	$13,955 $84.58 p/Share	165 Reduced 0.61%	26,765 Class A Common Stock
Mar 03 2023	SELL Open market or private sale	$71,725 $87.47 p/Share	820 Reduced 2.95%	26,930 Class A Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	3,000 Added 9.76%	27,750 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	8,250 Added 25.0%	24,750 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	12,500 Added 43.1%	16,500 Class A Common Stock

Also insider at

SMMT

Summit Therapeutics Inc. Healthcare

Chief Accounting Officer

Bhaskar Anand

SVP, Chief Accounting Officer

Plano, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RETA shares.

Notify only if

Value

Insider Trading

Get notified when an Reata Pharmaceuticals Inc insider buys or sells RETA shares.

Notify only if

Operation

Value

Type

News

Receive news related to REATA PHARMACEUTICALS INC

Track Activities on RETA

Account